3 ms·
The double-blind thing seems a little pointless here, 75ug is on the small end of dosage but close to the informal 'standard' dose of 100uh, and intravenous del
by anigbrowl 4y ago
The double-blind thing seems a little pointless here, 75ug is on the small end of dosage but close to the informal 'standard' dose of 100uh, and intravenous delivery means very rapid onset compared to oral administration. It might have been more interesting to try with low doses that wouldn't necessarily give the feeling of tripping (visual artifacts etc).
The result is interesting but feels a bit like a formal statement of what everyone already knew to be distinctive about psychedelics. The actual numbers don't seem that dramatic. I'm a little skeptical about the drive to rehab LSD as a therapeutic product - both because I have doubts about mediation of psychedelic experience by clinicians, and because of the relatively long metabolic half-life, with a psychoactive dose typically lasting 8-12 hours. The combination of LSD and for-profit healthcare delivery as practiced in the US seems like an extremely poor match.